Literature DB >> 16297840

Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study.

Elizabeth Selvin1, Josef Coresh, Eyal Shahar, Lin Zhang, Michael Steffes, A Richey Sharrett.   

Abstract

BACKGROUND: Individuals with diabetes have a raised risk of stroke, but it is unclear whether sustained hyperglycaemia contributes to the development of cerebrovascular disease. Haemoglobin A1c (HbA(1c)), a measure of long-term glycaemia, is strongly related to retinopathy, nephropathy, and neuropathy in diabetes. We sought to assess the association between HbA(1c) and stroke in people with and without diabetes.
METHODS: 10,886 participants without diabetes and 1635 participants with diabetes in the ARIC study, who did not have cardiovascular disease, were followed up for incident ischaemic stroke over 8-10 years. We assayed HbA(1c) for all 167 stroke cases and a sample of 680 non-cases in the adults without diabetes and for the full cohort of 1635 adults with diabetes (including 89 stroke cases). We assessed the relation between HbA(1c) concentrations (in tertiles specific for individuals with and without diabetes) and incident ischaemic stroke during follow-up using Cox proportional hazards models, controlling for risk factors for stroke.
FINDINGS: The adjusted relative risks of stroke increased with increasing tertile of HbA1c in both adults without diabetes (p=0.02) and with diabetes (p<0.0001). Compared with adults without diabetes in the lowest tertile of HbA1c, the adjusted relative risks of stroke by HbA(1c) tertile were 1.18 (0.70-2.00) and 1.58 (0.94-2.66) in adults without diabetes and 1.75 (0.90-3.42), 2.29 (1.24-4.21), and 4.71 (2.69-8.25) in adults with diabetes.
INTERPRETATION: Raised HbA(1c) could be an independent risk factor for stroke in people with and without diabetes, with relative risks similar to those previously reported for coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297840     DOI: 10.1016/S1474-4422(05)70227-1

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  38 in total

1.  Glycated haemoglobin and cognitive decline: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  A L Christman; K Matsushita; R F Gottesman; T Mosley; A Alonso; J Coresh; F Hill-Briggs; A R Sharrett; E Selvin
Journal:  Diabetologia       Date:  2011-03-01       Impact factor: 10.122

2.  Mid-term Risk Stratification of Patients with a Myocardial Infarction and Atrial Fibrillation: Beyond GRACE and CHADS.

Authors:  Sérgio Barra; Rui Providência; Luís Paiva; Inês Almeida; Francisca Caetano; Paulo Dinis; António Leitão Marques
Journal:  J Atr Fibrillation       Date:  2013-12-31

3.  Impact of Diabetes Mellitus on Stroke and Survival in Patients With Atrial Fibrillation.

Authors:  Sri Harsha Patlolla; Hon-Chi Lee; Peter A Noseworthy; Waldemar E Wysokinski; David O Hodge; Eddie L Greene; Bernard J Gersh; Rowlens M Melduni
Journal:  Am J Cardiol       Date:  2020-06-30       Impact factor: 2.778

4.  Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.

Authors:  Elizabeth Selvin; Michael W Steffes; Hong Zhu; Kunihiro Matsushita; Lynne Wagenknecht; James Pankow; Josef Coresh; Frederick L Brancati
Journal:  N Engl J Med       Date:  2010-03-04       Impact factor: 91.245

5.  Association Between Midlife Risk Factors and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study.

Authors:  Emily L Johnson; Gregory L Krauss; Alexandra K Lee; Andrea L C Schneider; Jennifer L Dearborn; Anna M Kucharska-Newton; Juebin Huang; Alvaro Alonso; Rebecca F Gottesman
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

6.  Secondary prevention of stroke: Pleiotropic effects of optimal oral pharmacotherapy.

Authors:  Kiyoshi Kikuchi; Ko-Ichi Kawahara; Naoki Miura; Takashi Ito; Yoko Morimoto; Salunya Tancharoen; Nobuyuki Takeshige; Hisaaki Uchikado; Rokudai Sakamoto; Naohisa Miyagi; Chiemi Kikuchi; Narumi Iida; Naoto Shiomi; Terukazu Kuramoto; Masaru Hirohata; Ikuro Maruyama; Motohiro Morioka; Eiichiro Tanaka
Journal:  Exp Ther Med       Date:  2012-04-24       Impact factor: 2.447

7.  Are There Clinical Implications of Racial Differences in HbA1c? A Difference, to Be a Difference, Must Make a Difference.

Authors:  Elizabeth Selvin
Journal:  Diabetes Care       Date:  2016-08       Impact factor: 19.112

Review 8.  The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis.

Authors:  Jessica Hurtubise; Krystie McLellan; Kevin Durr; Oluwadara Onasanya; Daniel Nwabuko; Joseph Fomusi Ndisang
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

9.  Glycosylated hemoglobin for diagnosis of prediabetes in acute ischemic stroke patients.

Authors:  Branko N Huisa; Gulmohor Roy; Jorge Kawano; Ronald Schrader
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-07-17       Impact factor: 2.136

Review 10.  Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives.

Authors:  Dirk Sander; Mark T Kearney
Journal:  J Neurol       Date:  2009-04-29       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.